サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1675321

経口抗生物質市場：薬剤クラス別、用途別、薬剤原料別、抗菌スペクトル別、薬剤タイプ別、地域別、2025-2033年

Oral Antibiotics Market Report by Class, Application (Community-acquired Respiratory Tract Infections, Urinary Tract Infections, Dental and Others), Drug Origin, Spectrum of Activity, Drug Type, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 147 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
経口抗生物質市場：薬剤クラス別、用途別、薬剤原料別、抗菌スペクトル別、薬剤タイプ別、地域別、2025-2033年
出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経口抗生物質市場の世界市場規模は2024年に210億7,800万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに279億4,930万米ドルに達し、2025年から2033年にかけて3.18%の成長率（CAGR）を示すと予測しています。感染症の蔓延、高齢者人口の増加、薬剤耐性菌に対する効果的な治療に対する需要の高まり、個別化医療とゲノミクスのトレンドの高まりなどが、市場を牽引する主な要因です。

経口抗生物質は、主に細菌の増殖を抑制したり、体内から細菌を除去するために処方される医薬品です。通常、口から服用し、幅広い医療適応で利用されています。経口抗生物質によって治療される感染症の種類は様々で、皮膚、耳、喉、尿路感染症などの一般的な疾患から、ある種の肺炎のような複雑な疾患まで含まれます。これらの抗生物質は異なるクラスに分類され、それぞれ作用機序が異なります。よく処方されるクラスには、ペニシリン系、フルオロキノロン系、テトラサイクリン系、マクロライド系などがあります。それぞれのクラスは、異なるタイプの細菌を標的とし、特定の細菌感染症により効果的です。例えば、ペニシリン系は溶連菌感染症に広く使用され、フルオロキノロン系は特定のグラム陰性菌に対抗するために選択されます。その結果、経口抗生物質は現代ヘルスケアの重要な要素であり、多くの細菌感染症の治療を成功させるために、医療専門家によって広く処方されています。

経口抗生物質市場動向：

感染症の有病率の増加と、これらの疾患に対する利用可能な治療選択肢に関する一般市民の意識の高まりが、市場の成長を支える主な要因となっています。さらに、このような感染症を発症しやすい高齢者人口の拡大も、市場の成長を後押しする主な要因です。さらに、抗生物質の普及を促し、抗生物質耐性の出現を遅らせ、これらの薬剤の効果を長持ちさせることを目的とした抗生物質スチュワードシップ・プログラムが増加しています。これに伴い、抗生物質耐性の問題が深刻化しているため、研究者や製薬会社は既存の抗生物質クラスを変更し、多剤耐性菌に対応できる新しい抗生物質を開発せざるを得なくなり、製品採用率が加速しています。さらに、主要製薬企業や研究機関は、細菌の耐性パターンを予測し、薬剤と細菌の相互作用を理解し、新規抗生物質の発見を迅速化するために、創薬プロセスにおいて人工知能（AI）や機械学習（ML）を活用しています。これに伴い、治療効果を高め副作用を最小限に抑えるため、患者の遺伝的体質などの要因を考慮し、個々の患者に合わせた抗生物質治療を行う個別化医療とゲノミクスの台頭が、市場の成長を促進しています。その他の要因としては、薬剤耐性菌に対する効果的な治療に対する需要の高まり、ヘルスケアインフラの改善、新規経口抗生物質の継続的な上市、研究開発（R&D）活動への多額の投資などが挙げられ、これらは今後数年間の市場成長を促進すると予想されます。

本レポートで扱う主な質問

  • 世界の経口抗生物質市場はこれまでどのように推移してきたか？
  • 世界の経口抗生物質市場における促進要因、抑制要因、機会は何か？
  • 各促進要因、抑制要因、機会が世界の経口抗生物質市場に与える影響は？
  • 主要な地域市場とは？
  • 最も魅力的な経口抗生物質市場はどの国か？
  • クラス別の市場内訳は？
  • 経口抗生物質市場で最も魅力的なクラスは？
  • 適応別の市場内訳は？
  • 経口抗生物質市場で最も魅力的な適応は？
  • 薬剤原料別の市場内訳は？
  • 経口抗生物質市場で最も魅力的な薬剤原料は？
  • 抗菌スペクトルに基づく市場内訳は？
  • 経口抗生物質市場で最も魅力的な抗菌スペクトルは？
  • 薬剤タイプ別の市場内訳は？
  • 経口抗生物質市場で最も魅力的な薬剤タイプはどれか？
  • 世界の経口抗生物質市場の競合構造は？
  • 世界の経口抗生物質市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の経口抗生物質市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：クラス別

  • ベータラクタムおよびベータラクタマーゼ阻害剤
    • 主要セグメント
      • ペニシリン
      • セファロスポリン
      • その他
  • キノロン
  • マクロライド
  • その他

第7章 市場内訳：適応別

  • 市中感染性呼吸器感染症（CARTI）
    • 主要セグメント
      • 上気道感染症（URTI）
      • 下気道感染症（LRTI）
  • 尿路感染症（UTI）
  • 歯科
    • 主要セグメント
      • 併剤
      • 単剤
  • その他

第8章 市場内訳：薬剤原料別

  • 天然
  • 半合成
  • 合成

第9章 市場内訳：抗菌スペクトル別

  • 広域
  • 狭域

第10章 市場内訳：薬剤タイプ別

  • ブランド
  • ジェネリック

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第12章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bayer AG
    • Cipla Inc
    • Gilead Sciences Inc
    • Janssen Inc.（Johnson & Johnson Services, Inc）
    • Pfizer Inc.
    • Roche Holding AG
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Oral Antibiotics Market: Major Drivers and Challenges
  • Figure 2: Global: Oral Antibiotics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Oral Antibiotics Market: Breakup by Class (in %), 2024
  • Figure 5: Global: Oral Antibiotics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Oral Antibiotics Market: Breakup by Drug Origin (in %), 2024
  • Figure 7: Global: Oral Antibiotics Market: Breakup by Spectrum of Activity (in %), 2024
  • Figure 8: Global: Oral Antibiotics Market: Breakup by Drug Type (in %), 2024
  • Figure 9: Global: Oral Antibiotics Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Oral Antibiotics (Beta Lactam and Beta Lactamase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Oral Antibiotics (Beta Lactam and Beta Lactamase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Oral Antibiotics (Quinolone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Oral Antibiotics (Quinolone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Oral Antibiotics (Macrolide) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Oral Antibiotics (Macrolide) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Oral Antibiotics (Other Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Oral Antibiotics (Other Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Oral Antibiotics (Community-acquired Respiratory Tract Infections (CARTIs)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Oral Antibiotics (Community-acquired Respiratory Tract Infections (CARTIs)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Oral Antibiotics (Urinary Tract Infections (UTIs)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Oral Antibiotics (Urinary Tract Infections (UTIs)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Oral Antibiotics (Dental) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Oral Antibiotics (Dental) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Oral Antibiotics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Oral Antibiotics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Oral Antibiotics (Natural) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Oral Antibiotics (Natural) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Oral Antibiotics (Semisynthetic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Oral Antibiotics (Semisynthetic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Oral Antibiotics (Synthetic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Oral Antibiotics (Synthetic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Oral Antibiotics (Broad-spectrum Antibiotic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Oral Antibiotics (Broad-spectrum Antibiotic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Oral Antibiotics (Narrow Spectrum Antibiotic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Oral Antibiotics (Narrow Spectrum Antibiotic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Oral Antibiotics (Branded) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Oral Antibiotics (Branded) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Oral Antibiotics (Generics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Oral Antibiotics (Generics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: North America: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: North America: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United States: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United States: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Canada: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Canada: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Asia-Pacific: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Asia-Pacific: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: China: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: China: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Japan: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Japan: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: India: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: India: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: South Korea: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: South Korea: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Australia: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Australia: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Indonesia: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Indonesia: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Europe: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Europe: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Germany: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Germany: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: France: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: France: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: United Kingdom: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: United Kingdom: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Italy: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Italy: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Spain: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Spain: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Russia: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Russia: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Latin America: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Latin America: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Brazil: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Brazil: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Mexico: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Mexico: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Others: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Others: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Middle East and Africa: Oral Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Middle East and Africa: Oral Antibiotics Market: Breakup by Country (in %), 2024
  • Figure 88: Middle East and Africa: Oral Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Oral Antibiotics Industry: Drivers, Restraints, and Opportunities
  • Figure 90: Global: Oral Antibiotics Industry: Value Chain Analysis
  • Figure 91: Global: Oral Antibiotics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oral Antibiotics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Oral Antibiotics Market Forecast: Breakup by Class (in Million USD), 2025-2033
  • Table 3: Global: Oral Antibiotics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Oral Antibiotics Market Forecast: Breakup by Drug Origin (in Million USD), 2025-2033
  • Table 5: Global: Oral Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million USD), 2025-2033
  • Table 6: Global: Oral Antibiotics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 7: Global: Oral Antibiotics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Oral Antibiotics Market: Competitive Structure
  • Table 9: Global: Oral Antibiotics Market: Key Players
目次
Product Code: SR112025A8355

The global oral antibiotics market size reached USD 21,078.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 27,949.3 Million by 2033, exhibiting a growth rate (CAGR) of 3.18% during 2025-2033. The increasing prevalence of infectious diseases, expanding geriatric population, escalating demand for effective treatments against drug-resistant bacteria, and the growing trend of personalized medicine and genomics represent some of the key factors driving the market.

Oral antibiotics are pharmaceutical agents primarily prescribed to inhibit bacterial growth or eliminate bacteria from the body. They are usually taken by mouth and are utilized across a wide range of medical applications. The types of infections treated by oral antibiotics vary and include common ailments such as skin, ear, throat, and urinary tract infections and more complex conditions like certain types of pneumonia. These antibiotics are categorized into different classes, each with a distinct mechanism of action. Some commonly prescribed classes include penicillins, fluoroquinolones, tetracyclines, and macrolides. Each class targets different types of bacteria and is more effective for specific bacterial infections. For instance, penicillins are widely used for streptococcal infections, while fluoroquinolones may be chosen to combat certain gram-negative bacteria. As a result, oral antibiotics are a key element of modern healthcare and are widely prescribed by healthcare professionals to enable the successful treatment of numerous bacterial infections.

Oral Antibiotics Market Trends:

The increasing prevalence of infectious diseases and the rising public awareness about the available treatment options for these conditions represent the primary factors supporting market growth. Moreover, the expanding geriatric population that is more susceptible to developing such infections is another major factor fueling the market growth. In addition, there has been a rise in antibiotic stewardship programs aimed at encouraging the widespread use of antibiotics, slowing down the emergence of antibiotic resistance, and ensuring the prolonged effectiveness of these drugs. Along with this, the growing issue of antibiotic resistance has compelled researchers and pharmaceutical companies to modify existing classes and develop new antibiotics capable of treating multi-drug resistant bacteria, thereby accelerating the product adoption rate. Furthermore, the leading pharmaceutical companies and research institutes are leveraging artificial intelligence (AI) and machine learning (ML) in the drug discovery process to predict bacterial resistance patterns, understand drug-bacteria interactions, and expedite the discovery of novel antibiotics. In line with this, the emergence of personalized medicine and genomics, which involves tailoring antibiotic treatment to individual patients by considering factors such as their genetic makeup to enhance treatment effectiveness and minimize side effects, has catalyzed market growth. Other factors, including escalating demand for effective treatments against drug-resistant bacteria, improving healthcare infrastructure, the continual launch of novel oral antibiotics, and heavy investments in research and development (R&D) activities, are also anticipated to propel the market growth in the coming years.

Key Market Segmentation:

Class Insights:

  • Beta Lactam and Beta Lactamase Inhibitors
  • Penicillin
  • Cephalosporin
  • Others
  • Quinolone
  • Macrolide
  • Others

Application Insights:

  • Community-acquired Respiratory Tract Infections (CARTIs)
  • Upper Respiratory Tract Infections (URTI)
  • Lower Respiratory Tract Infections (LRTIs)
  • Urinary Tract Infections (UTIs)
  • Dental
  • Combination
  • Monotherapies
  • Others

Drug Origin Insights:

  • Natural
  • Semisynthetic
  • Synthetic

Spectrum of Activity Insights:

  • Broad-spectrum Antibiotic
  • Narrow Spectrum Antibiotic

Drug Type Insights:

  • Branded
  • Generics

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia-Pacific was the largest market for oral antibiotics. Some of the factors driving the Asia-Pacific oral antibiotics market included its aging population, growing burden of infectious diseases, high healthcare expenditure, the presence of various key players, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global oral antibiotics market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bayer AG, Cipla Inc., Gilead Sciences Inc., Janssen Inc. (Johnson & Johnson Services, Inc.), Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global oral antibiotics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global oral antibiotics market?
  • What is the impact of each driver, restraint, and opportunity on the global oral antibiotics market?
  • What are the key regional markets?
  • Which countries represent the most attractive oral antibiotics market?
  • What is the breakup of the market based on the class?
  • Which is the most attractive class in the oral antibiotics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the oral antibiotics market?
  • What is the breakup of the market based on the drug origin?
  • Which is the most attractive drug origin in the oral antibiotics market?
  • What is the breakup of the market based on the spectrum of activity?
  • Which is the most attractive spectrum of activity in the oral antibiotics market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the oral antibiotics market?
  • What is the competitive structure of the global oral antibiotics market?
  • Who are the key players/companies in the global oral antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oral Antibiotics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Class

  • 6.1 Beta Lactam and Beta Lactamase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Penicillin
      • 6.1.2.2 Cephalosporin
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Quinolone
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Macrolide
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Community-acquired Respiratory Tract Infections (CARTIs)
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Upper Respiratory Tract Infections (URTI)
      • 7.1.2.2 Lower Respiratory Tract Infections (LRTIs)
    • 7.1.3 Market Forecast
  • 7.2 Urinary Tract Infections (UTIs)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dental
    • 7.3.1 Market Trends
    • 7.3.2 Key Segments
      • 7.3.2.1 Combination
      • 7.3.2.2 Monotherapies
    • 7.3.3 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Origin

  • 8.1 Natural
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Semisynthetic
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Synthetic
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Spectrum of Activity

  • 9.1 Broad-spectrum Antibiotic
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Narrow Spectrum Antibiotic
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Drug Type

  • 10.1 Branded
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Generics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Bayer AG
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Cipla Inc
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Gilead Sciences Inc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Janssen Inc. (Johnson & Johnson Services, Inc)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
    • 16.3.5 Pfizer Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Roche Holding AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Sun Pharmaceutical Industries Ltd
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Teva Pharmaceutical Industries Ltd.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.